Annual Report from Cyxone AB for the period 1 January 2018 to 31 December 2018

Cyxone AB’s Annual Report for the financial year 2018 is now available at the company’s website (

Please see attached Annual Report as pdf.

Cyxone AB (publ)

Kjell G. Stenberg, CEO
Tel: +46 (0) 723 816 168
Adelgatan 21

221 22 Malmö

About Cyxone
Cyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The company’s drug portfolio is based on two technological pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body’s cells that are typically associated with various immune-related disorders. Cyxone’s technologies have the potential to address an unmet need and provide new effective and safe medicines that can improve the quality of life for patients affected by autoimmune diseases. The company has two drug candidates, T20K for MS in a preclinical program and Rabeximod for RA in clinical phase II-program. Cyxone’s Certified Adviser on the Nasdaq First North is Mangold Fondkommission AB, +46 (0)8-503 015 50,  


About Us

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for disorders of the immune system such as rheumatoid arthritis, multiple sclerosis, as well as a treatment for virally induced respiratory disorders. Rabeximod is a Phase 2 therapeutic candidate with a unique mode of action in rheumatoid arthritis and treating moderate Covid-19 infections. T20K is a Phase 1 therapeutic candidate for treatment of multiple sclerosis. Certified Adviser is Mangold Fondkommission AB, +46 (0)8 503 015 50, For more information, please visit


Documents & Links